Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Shashen Maidong Granules for chronic cough due to cough-variant asthma
CTR20243915Phase 3Completed
- Sponsor
- Hubei Liyi Pharmaceutical Technology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of shashen maidong granules in chronic cough, cough variant asthma (CVA), sponsored by Hubei Liyi Pharmaceutical Technology. Started Nov 2024; status: completed.
02
Drugs
shashen maidong granules
03
Conditions
chronic coughcough variant asthma (CVA)
Beyond the preview
Go deeper on CTR20243915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243915.